Cancer News

Immunotherapy comparable to chemo for some advanced stomach cancers (06/04/2019)

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The immunotherapy, called pembrolizumab (Keytruda), was most effective for patients whose cancers carry high levels of a molecule... Continue Reading

FDA Approves Lonsurf® for Treatment of Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (03/08/2019)

The United States Food and Drug Administration (FDA) has approved Lonsurf® (trifluridine/tipiracil)) as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. About Lonsurf Lonsurf consists of... Continue Reading

Diagnosed with Gastric Cancer: 10 Tips on How to Get The Most From Your Doctor (12/21/2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with gastric cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you feel comfortable …

Continue reading "Diagnosed with Gastric Cancer: 10 Tips on How to Get The Most From Your Doctor"

New Standard of Care for Treatment of Resectable Gastric Cancer (10/03/2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable esophago-gastric cancer is poor. Five-year overall survival is around 25% with surgery, and is increased to 36% by …

Continue reading "New Standard of Care for Treatment of Resectable Gastric Cancer"

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (09/25/2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted …

Continue reading "The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer"

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer (09/18/2017)

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach cancer (gastric cancer), is the third leading cause of cancer-related deaths worldwide. Overall, the 5-year survival rate for patients with gastric cancer …

Continue reading "Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer"

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (02/06/2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments. About Gastric Cancer Gastric cancer refers to cancer of the …

Continue reading "Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer"

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01/23/2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause …

Continue reading "Proton Beam Therapy May Improve Outcomes for Esophageal Cancer"

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer? (12/08/2016)

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be … Continue reading "Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?"

Novel Antibody Improves Survival in Advanced Stomach Cancer (06/28/2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, … Continue reading "Novel Antibody Improves Survival in Advanced Stomach Cancer"